143 related articles for article (PubMed ID: 29242582)
1. Outcomes of patients with peripheral T-cell lymphoma in first complete remission: data from three tertiary Asian cancer centers.
Tang T; Khoo LP; Lim C; Ham JS; Kim SJ; Hong H; Phipps C; Lee YS; Tao M; Quek R; Farid M; Lin T; Kim WS; Lim ST
Blood Cancer J; 2017 Dec; 7(12):653. PubMed ID: 29242582
[No Abstract] [Full Text] [Related]
2. Therapeutic effects and influencing factors in sixty-eight cases of peripheral T-cell lymphoma unspecified.
Kangsheng G; Di W; Jingjing W
Tumori; 2014; 100(1):21-5. PubMed ID: 24675486
[TBL] [Abstract][Full Text] [Related]
3. Autologous stem cell transplantation as consolidation therapy for patients with peripheral T cell lymphoma in first remission: long-term outcome and risk factors analysis.
Czyz A; Romejko-Jarosinska J; Helbig G; Knopinska-Posluszny W; Poplawska L; Piatkowska-Jakubas B; Hawrylecka D; Nasilowska-Adamska B; Dytfeld D; Lojko-Dankowska A; Kopinska A; Boguradzki P; Walewski J; Kyrcz-Krzemien S; Hellmann A; Komarnicki M
Ann Hematol; 2013 Jul; 92(7):925-33. PubMed ID: 23471671
[TBL] [Abstract][Full Text] [Related]
4. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01.
d'Amore F; Relander T; Lauritzsen GF; Jantunen E; Hagberg H; Anderson H; Holte H; Österborg A; Merup M; Brown P; Kuittinen O; Erlanson M; Østenstad B; Fagerli UM; Gadeberg OV; Sundström C; Delabie J; Ralfkiaer E; Vornanen M; Toldbod HE
J Clin Oncol; 2012 Sep; 30(25):3093-9. PubMed ID: 22851556
[TBL] [Abstract][Full Text] [Related]
5. Comparison of long-term clinical outcomes of CHOP chemotherapy between Japanese patients with nodal peripheral T-cell lymphomas and those with diffuse large B-cell lymphoma in the study group of the Tohoku Hematology Forum.
Akagi T; Takahashi N; Yamaguchi K; Ishizawa K; Murai K; Tajima K; Ikeda K; Kameoka Y; Kameoka J; Ito S; Kato Y; Noji H; Shichishima T; Itoh J; Ichinohasama R; Harigae H; Ishida Y; Sawada K
J Clin Exp Hematop; 2011; 51(1):29-35. PubMed ID: 21628858
[TBL] [Abstract][Full Text] [Related]
6. Clinical and prognostic differences between ALK-negative anaplastic large cell lymphoma and peripheral T cell lymphoma, not otherwise specified: a single institution experience.
Deng XW; Zhang XM; Wang WH; Wang SL; Jin J; Fang H; Ren H; Liu YP; He XH; Dong M; Song YW; Li YX
Ann Hematol; 2016 Aug; 95(8):1271-80. PubMed ID: 27209536
[TBL] [Abstract][Full Text] [Related]
7. The impact of stem cell transplantation on the natural course of peripheral T-cell lymphoma: a real-world experience.
Rohlfing S; Dietrich S; Witzens-Harig M; Hegenbart U; Schönland S; Luft T; Ho AD; Dreger P
Ann Hematol; 2018 Jul; 97(7):1241-1250. PubMed ID: 29549411
[TBL] [Abstract][Full Text] [Related]
8. Analysis of prognostic factors for survival in 75 Chinese patients with peripheral T-cell lymphoma.
Zhu Q; Wang H; Ruan J; Guo L; Zhao S; Zhang W; Wang Q; Jin Z; Chen X; Sun A; Wu D; Han Y
Leuk Lymphoma; 2014 Apr; 55(4):959-61. PubMed ID: 23885796
[No Abstract] [Full Text] [Related]
9. Treatment response and overall outcome of patients with relapsed and refractory peripheral T-cell lymphoma compared to diffuse large B-cell lymphoma.
Puig N; Wang L; Seshadri T; al-Farsi K; Keating A; Crump M; Kuruvilla J
Leuk Lymphoma; 2013 Mar; 54(3):507-13. PubMed ID: 22897731
[TBL] [Abstract][Full Text] [Related]
10. Phase I dose escalation study of the anti-CD2 monoclonal antibody, siplizumab, with DA-EPOCH-R in aggressive peripheral T-cell lymphomas.
Roswarski J; Roschewski M; Lucas A; Melani C; Pittaluga S; Jaffe ES; Steinberg SM; Waldmann TA; Wilson WH
Leuk Lymphoma; 2018 Jun; 59(6):1466-1469. PubMed ID: 29032710
[No Abstract] [Full Text] [Related]
11. Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter study.
Reboursiere E; Le Bras F; Herbaux C; Gyan E; Clavert A; Morschhauser F; Malak S; Sibon D; Broussais F; Braun T; Fornecker LM; Garidi R; Tricot S; Houot R; Joly B; Abarah W; Choufi B; Pham AD; Gac AC; Fruchart C; Marin E; Safar V; Parcelier A; Maisonneuve H; Bachy E; Cartron G; Jaccard A; Tournilhac O; Rossi C; Schirmer L; Martignoles JA; Gaulard P; Tilly H; Damaj G;
Oncotarget; 2016 Dec; 7(51):85573-85583. PubMed ID: 27458168
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma.
Chihara D; Pro B; Loghavi S; Miranda RN; Medeiros LJ; Fanale MA; Hagemeister FB; Fayad LE; Romaguera JE; Samaniego F; Neelapu SS; Younes A; Fowler NH; Rodriguez MA; Wang M; Kwak LW; McLaughlin P; Dang NH; Oki Y
Br J Haematol; 2015 Nov; 171(4):509-16. PubMed ID: 26260306
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine-based combination regimen in patients with peripheral T-cell lymphoma.
Dong M; He XH; Liu P; Qin Y; Yang JL; Zhou SY; Yang S; Zhang CG; Gui L; Zhou LQ; Shi YK
Med Oncol; 2013 Mar; 30(1):351. PubMed ID: 23269584
[TBL] [Abstract][Full Text] [Related]
14. Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers.
Fossard G; Broussais F; Coelho I; Bailly S; Nicolas-Virelizier E; Toussaint E; Lancesseur C; Le Bras F; Willems E; Tchernonog E; Chalopin T; Delarue R; Gressin R; Chauchet A; Gyan E; Cartron G; Bonnet C; Haioun C; Damaj G; Gaulard P; Fornecker L; Ghesquières H; Tournilhac O; da Silva MG; Bouabdallah R; Salles G; Bachy E
Ann Oncol; 2018 Mar; 29(3):715-723. PubMed ID: 29253087
[TBL] [Abstract][Full Text] [Related]
15. The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study.
Park SI; Horwitz SM; Foss FM; Pinter-Brown LC; Carson KR; Rosen ST; Pro B; Hsi ED; Federico M; Gisselbrecht C; Schwartz M; Bellm LA; Acosta M; Advani RH; Feldman T; Lechowicz MJ; Smith SM; Lansigan F; Tulpule A; Craig MD; Greer JP; Kahl BS; Leach JW; Morganstein N; Casulo C; Shustov AR;
Cancer; 2019 May; 125(9):1507-1517. PubMed ID: 30694529
[TBL] [Abstract][Full Text] [Related]
16. Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas.
Fanale MA; Horwitz SM; Forero-Torres A; Bartlett NL; Advani RH; Pro B; Chen RW; Davies A; Illidge T; Uttarwar M; Lee SY; Ren H; Kennedy DA; Shustov AR
Blood; 2018 May; 131(19):2120-2124. PubMed ID: 29507077
[TBL] [Abstract][Full Text] [Related]
17. Complete response of relapsed angioimmunoblastic T-cell lymphoma following therapy with bevacizumab.
Aguiar Bujanda D
Ann Oncol; 2008 Feb; 19(2):396-7. PubMed ID: 18245132
[No Abstract] [Full Text] [Related]
18. DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center.
Mikesch JH; Kuhlmann M; Demant A; Krug U; Thoennissen GB; Schmidt E; Kessler T; Schliemann C; Pohlen M; Mohr M; Evers G; Köhler G; Wessling J; Mesters R; Müller-Tidow C; Berdel WE; Thoennissen NH
Ann Hematol; 2013 Aug; 92(8):1041-8. PubMed ID: 23532626
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcome of patients with peripheral T-cell lymphoma treated with first-line intensive chemotherapy followed by autologous stem cell transplantation.
Prochazka V; Faber E; Raida L; Papajik T; Vondrakova J; Rusinakova Z; Kucerova L; Myslivecek M; Indrak K
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2011 Mar; 155(1):63-9. PubMed ID: 21475380
[TBL] [Abstract][Full Text] [Related]
20. Prognostic relevance of CD20 expression in peripheral T-cell lymphomas: a multi-center retrospective study.
Toya T; Nannya Y; Hangaishi A; Shiseki M; Shimoyama T; Sakamaki H; Motoji T; Usuki K; Nakamura F; Kurokawa M
Leuk Lymphoma; 2016; 57(4):961-4. PubMed ID: 26366623
[No Abstract] [Full Text] [Related]
[Next] [New Search]
